Characterization of binding sites for β-adrenergic agonists and vasoactive intestinal peptide in the rat Harderian gland
✍ Scribed by Guerrero, Juan M.; Osuna, Carmen; Molinero, Patrocinio; Caraballo, Maria I.; Harmouch, Ahmed; Pozo, David; Rafii-El-Idrissi, Mohammed; Garcia-Macias, Juan F.; Calvo, Juan R.
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 546 KB
- Volume
- 34
- Category
- Article
- ISSN
- 1059-910X
No coin nor oath required. For personal study only.
✦ Synopsis
Vasoactive intestinal peptide (VIP) receptors and p-adrenergic receptors were investigated in rat Harderian gland membranes using '251-VIP and 125I-cyanopindolol(125I-CYP), respectively, as ligands. The receptor bindings were rapid, reversible, saturable, specific, and dependent on time, temperature, and membrane concentration. The stoichiometric data suggested the presence of two classes of VIP receptors with Kd values of 0.36 and 65.37 nM and binding capacities of 323 and 39,537 fmol W / m g protein, respectively. The interaction showed a high degree of specificity, as suggested by competitive displacement experiments with several peptides structurally or not structurally related to VIP as follows: VIP > helodermin > rGRF > PHI >> secretin.
Glucagon, somatostatin, insulin, and pancreastatin were ineffective at concentrations up to 1 pM. However, the stoichiometric data suggest the presence of one class of binding sites for 1251-CYP. The Kd for the single site was 290 pM with a binding capacity of 32 pmoVL. The pharmacological characterization of 1251-CYP binding to membranes showed that only isoproterenol, a p-adrenergic agonist, and norepinephrine, a n ap-adrenergic agonist, was as effective as propranolol in inhibiting 1251-CYP binding to Harderian gland membranes. However, al-and a2-adrenergic agonists and blockers such as methoxamine, prazosin, clonidine, and yohimbine were shown to be ineffective. These results demonstrate the presence of specific VIP and p-adrenergic receptors in the Harderian gland and suggest a role for VIP and p-adrenergic agonists in the physiology of this gland.